Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 144, Issue 1, 2009, Pages 78-85

  Karlsson, Claes ^a,b   Lundin, Jeanette ^a,b   Kimby, Eva ^a   Kennedy, Ben ^c   Moreton, Paul ^d   Hillmen, Peter ^d   Österborg, Anders ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Alemtuzumab; Chronic lymphocytic leukaemia; Monoclonal antibodies; Subcutaneous injection

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; BETAMETHASONE; COTRIMOXAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; PARACETAMOL; VALACICLOVIR;

ADENOVIRUS INFECTION; ADULT; ADVANCED CANCER; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL PNEUMONIA; BLOOD TOXICITY; CANCER FATIGUE; CANCER PATIENT; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COUGHING; CYTOMEGALOVIRUS; DEATH; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPNEA; ERYTHEMA; FEMALE; HUMAN; IMMUNOTHERAPY; INJECTION SITE REACTION; LEUKEMIA RELAPSE; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RIGOR; SKIN BRUISING; SKIN EDEMA; SKIN MANIFESTATION; SKIN PAIN; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CONTUSIONS; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; THIGH; TREATMENT OUTCOME;

EID: 57449111685     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07451.x     Document Type: Article

References (18)

1. Andritsos, L.A., Johnson, A.J., Lozanski, G., Blum, W., Kefauver, C., Awan, F., Smith, L.L., Lapalombella, R., May, S.E., Raymond, C.A., Wang, D.S., Knight, R.D., Ruppert, A.S., Lehman, A., Jarjoura, D., Chen, C.S. Byrd, J.C. (2008) Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukaemia. Journal of Clinical Oncology, 26, 2519 2525.
2. Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S. Rai, K. (1996) National Cancer Institute - Sponsored working group guidelines for chronic lymphocytic leukaemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990 4997.
3. Coiffier, B., Lepretre, S., Pedersen, L.M., Gadeberg, O., Fredriksen, H., van Oers, M.H., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., Walewski, J., Flensburg, M., Petersen, J. Robak, T. (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia: a phase 1-2 study. Blood, 111, 1094 1100.
4. Ferrajoli, A., Lee, B.N., Schlette, E.J., O'Brien, S.M., Gao, H., Wen, S., Wierda, W.G., Estrov, Z., Faderl, S.H., Cohen, E.N., Li, C., Reuben, J.M. Keating, M.J. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukaemia. Blood, 111, 5291 5297.
5. Gilleece, M.H. Dexter, T.M. (1993) Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood, 82, 807 812.
6. Hale, G., Rebello, P., Brettman, L., Fegan, C., Kennedy, B., Kimby, E., Leach, M., Lundin, J., Mellstedt, H., Moreton, P., Rawstron, A., Waldmann, H., Osterborg, A. Hillmen, P. (2004) Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukaemia following intravenous or subcutaneous routes of administration. Blood, 104, 948 955.
7. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukaemia: a report from the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) updating the National Cancer Institute-Working Group NCI-WG 1996 guidelines. Blood, 111, 5446 5456.
8. Hillmen, P., Skotnicki, A.B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C. Mayer, J. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukaemia. Journal of Clinical Oncology, 25, 5616 5623.
9. Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. Rai, K.R. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 3554 3561.
10. Lundin, J., Kimby, E., Björkholm, M., Broliden, P-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H. Österborg, A. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukaemia (B-CLL). Blood, 100, 768 773.
11. O'Brien, S.M., Keating, M.J. Mocarski, E.S. (2006) Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukaemia treated with alemtuzumab. Clinical Lymphoma & Myeloma, 7, 125 130.
12. O'Brien, S., Ravandi, F., Riehl, T., Wierda, W., Huang, X., Tarrand, J., O'Neal, B., Kantarjian, H. Keating, M. (2008) Vanganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood, 111, 1816 1819.
13. Österborg, A. (2006) Practical considerations for alemtuzumab therapy in B-cell chronic lymphocytic leukaemia (B-CLL). Cutting Edge, 11, 3 6.
14. Österborg, A., Lundin, J., Karlsson, C., Kimby, E. Mellstedt, H. (2006) Strategies in the management of alemtuzumab-related side effects. Seminars in Oncology, 33, S29 S35.
15. Rossmann, E., Lundin, J., Lenkei, R., Mellstedt, H. Österborg, A. (2001) Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukaemias with monoclonal antibodies. The Hematology Journal, 2, 300 306.
16. Rossmann, E., Lenkei, R., Lundin, J., Mellstedt, H. Österborg, A. (2007) Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukaemia. Cytometry Part B: Clinical Cytometry, 72, 450 457.
17. Sebrango, A., De la Iglesia, A., Garcia-Vela, J.A., Ferre, S., Ruiz, E., Navarro, B., Fores, R., Carbonell, F., Snachez-Godoy, P., Fernandez, M.N. Garcia-Marco, J.A. (2007) Alemtuzumab as a single agent or combined with methylprednisolone (MPD) or fludarabine (FDR) for the treatment of CLL patients with p53 and ATM deletions. Blood, 110, 918A.
18. Stilgenbauer, S., Winkler, D., Bühler, A., Zenz, T., Groner, S., Busch, R., Hensel, M., Dührsen, U., Finke, J., Dreger, P., Jäger, U., Lengfelder, E., Trümper, L., Söling, U., Schlag, R., Hallek, M. Döhner, H. (2007) Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG). Blood, 110, 918A.